SOFINNOVA-PARTNERS
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that its portfolio company, Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in the development of therapeutic peptides for rare endocrine and related diseases has entered into a definitive agreement with AstraZeneca for its acquisition, with an upfront purchase price of $800 million and a potential milestone payment of $250 million.
“We are proud of the remarkable achievements of our team, developing a therapeutic portfolio tackling unmet needs for rare endocrine and related diseases. Last year's Series C financing laid the foundation for the momentum with eneboparatide, propelling us forward to partner with Alexion, AstraZeneca Rare Disease, to bring innovative therapies to patients with rare endocrinology diseases globally. We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.
“Congratulations to the Amolyt team on its proposed acquisition by AstraZeneca. Leading Amolyt’s Series C financing round in January 2023 was an honor. This milestone demonstrates Sofinnova's investment thesis in action, showcasing our commitment to supporting innovative European companies during their critical growth stage. In Amolyt's case, it exemplifies our commitment to supporting a company developing groundbreaking solutions in a later stage of development for rare disease patients,” noted Cédric Moreau, Partner with the Sofinnova Crossover Strategy.
“This marks our second successful exit within the past year, reaffirming the strength of our Crossover Strategy and our longstanding presence in the endocrinology space. Thierry, is a visionary leader and embodies the serial biotech entrepreneurs we partner with,” added Antoine Papiernik, Managing Partner & Chairman of Sofinnova Partners.
Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease, said: “Chronic hypoparathyroid patients face a significant need for an alternative to current supportive therapies, which do not address the underlying hormone deficiency. As leaders in rare disease, Alexion is uniquely positioned to drive the late-stage development and global commercialisation of eneboparatide, which has the potential to lessen the often debilitating impact of low parathyroid hormone and avoid the risks of high-dose calcium supplementation. We believe this programme, together with Amolyt’s talented team, expertise, and earlier pipeline, will enable our expansion into rare endocrinology.”
Amolyt’s clinical pipeline includes differentiated therapeutic peptides for the treatment of underserved rare endocrine disease. Eneboparatide (AZP-3601) is an investigational daily subcutaneous injectable parathyroid hormone receptor 1 (PTHR1) agonist for the treatment of hypoparathyroidism, that is currently in Phase 3. AZP-3813 is a peptide growth hormone receptor antagonist for the potential treatment of acromegaly that is in Phase 1.
Terms of the agreement
Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05B, on a cash and debt free basis. This includes $800 million upfront at deal closing, plus the right for Amolyt Pharma’s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone.
Subject to the satisfaction of customary closing conditions in the acquisition agreement, including regulatory clearances, the transaction is expected to close by the end of the third quarter of 2024.
Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.
About Amolyt Pharma
Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314071786/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Resilience Software Specialist Restrata Secures Growth Investment From SEP13.2.2025 01:01:00 CET | Press release
Restrata, the operational resilience software and service provider to global enterprises, including some of the world’s largest energy and industrial companies, has raised investment from Scottish Equity Partners (SEP) to meet growing market demand. The investment will support accelerated product development and AI-powered enhancements as well as expansion of existing operations in North America, Europe, and the Middle East. Increased adoption of the London-based company’s resilienceOS platform, which helps enterprise clients protect their people, assets and operations globally, saw resilienceOS revenue surge more than 50% in 2024. Enterprises are increasingly focused on people safety and operational resilience due to unprecedented levels of global uncertainty. In response, business leaders are seeking sophisticated technology to mitigate, manage, and respond to operational disruption while maintaining visibility and control over day-to-day operations. These threats range from localise
Suzano sets sales record in 2024 with new mill in Mato Grosso do Sul state and acquisition in the U.S.12.2.2025 23:31:00 CET | Press release
Suzano, the world’s largest pulp producer, announces its quarterly results for both the final quarter (4Q24) and the full year (2024). Pulp and paper sales reached a new record of 12.3 million tonnes, rising 7% on 2023, mainly driven by the additional capacity from the new pulp mill in Ribas do Rio Pardo in Mato Grosso do Sul state. Further capacity from the recent acquisition of paperboard mills in the United States has also contributed to the record sales volume. The higher sales volumes and favorable exchange rates boosting export revenues resulted in net revenues of R$47.4 billion in 2024, 19% higher than in 2023. Adjusted EBITDA grew 31%, to R$23.8 billion, while operational cash generation increased 40%, reaching R$16.2 billion. Suzano reported a net loss of R$6.7 billion due to the accounting impact of US dollar denominated debt and hedging operations translating into Brazilian Real. There is no immediate cash impact of this accounting adjustment and the potential cash effect wi
Andersen Global udvider de juridiske kompetencer i Argentina12.2.2025 18:58:00 CET | Pressemeddelelse
Andersen Global fortsætter med at udbygge tilstedeværelsen af den juridiske Latinamerika-platform gennem samarbejdsaftaler med MBP Partners og Schmukler IP, to advokatvirksomheder med base i Buenos Aires. MBP Partners, der blev stiftet i 2016 af Ignacio Meggiolaro og Victoria Bengochea, er anerkendt af Chambers , The Legal 500ogIFLR 1000 som førende leverandør af juridiske services i Latinamerika. Virksomheden rådgiver lokale og internationale kunder på områder som compliance og virksomhedsledelse. De har specialiseret sig i selskabsret og M&A-lovgivning, bankvirksomhed og kapitalmarkeder, minedrift og naturressourcer, compliance og korruptionsbekæmpelse, skatteret og udenrigshandel, fintech, hvidvaskning af penge, energi og kulbrinter, lovgivning om virksomhedsledelse og infrastruktur. Schmukler IP blev stiftet i 1947, og virksomheden har et erfarent team af fagfolk inden for industriel ejendomsret og jura. Virksomheden tilbyder omfattende services inden for intellektuel ejendomsret,
The smarter E Europe: Smart Integration Saves Cash and Stabilizes Grids12.2.2025 17:52:00 CET | Press release
‘Accelerating Integrated Energy Solutions’ - this is the motto of The smarter E Europe 2025, which will take place this year from 7 to 9 May at Messe München.Smart integration is crucial in the evolving energy and mobility sectors. Energy management systems (EMS) for prosumers and businesses have shifted from a nice-to-have to a must-have, making them a key topic at this year’s event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250212149082/en/ At The smarter E Europe 2025, visitors will find everything for the smart interaction of PV, storage, e-mobility and energy management. (Photo: Solar Promotion GmbH) GridX, a smart energy company, estimates that the European Home Energy Management System (HEMS) market will expand 11-fold by 2030 across Denmark, Germany, the UK, Italy, the Netherlands, Austria, Sweden, and Spain. This rapid growth reflects increasing demand and evolving regulations. Regulatory and market requirement
Dubai Achieves World’s Lowest Electricity Customer Minutes Lost (CML) at 0.94 Minutes Per Year, Breaking Its 2023 Record12.2.2025 17:37:00 CET | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA), announced that DEWA achieved the world’s lowest electricity Customer Minutes Lost (CML) in 2024, recording just 0.94 minutes per customer. This breaks its record of 1.06 minutes in 2023 and is significantly lower than the 15-minute average of leading European utilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250212414260/en/ HE Saeed Mohammed Al Tayer, MD & CEO of DEWA (Photo: AETOSWire) "We are guided by the vision and directives of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, to make Dubai the world’s best city for quality of life. To achieve this, we continuously develop Dubai's electricity and water infrastructure through innovation, which we adopt as a key approach to managing facilities through a smart and interconnected network. This enables us to deliver
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom